Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lauren N. Kormelink
Observed names:
L. Kormelink,
Lauren Kormelink
Institutions:
University of Kentucky HealthCare,
University of Kentucky
Observed institutions:
University of North Carolina at Chapel Hill,
University of Kentucky HealthCare,
University of Kentucky,
Aarhus University Hospital,
Rigshospitalet,
Indiana University,
Technical University of Denmark
show all 7
ORCID:
0000-0003-1980-6031
Observed ORCID:
0000-0003-1980-6031
OpenAlex ID:
A5039352163
The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series
2021
·
Hunter Ragan
, Elizabeth Autry
, et al.
·
Pediatric Pulmonology
·
29
Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics
2019
·
David C. Young
, Elizabeth Autry
, et al.
·
Pediatric Pulmonology
·
26
Retrospective review of vancomycin monitoring via trough only versus two‐point estimated area under the curve in pediatric and adult patients with cystic fibrosis
2022
·
Billie Mitchell
, Lauren Kormelink
, et al.
·
Pediatric Pulmonology
·
10
Assessment of long‐term medication adherence with cystic fibrosis: An integrated approach
2023
·
Thomas Platt
, Lauren N. Kormelink
, et al.
·
Pediatric Pulmonology
·
6
PDF
A decade of change: The evolution of pharmacy services at U.S. cystic fibrosis centers
2023
·
Paige M. Grube
, Elizabeth B. Autry
, et al.
·
Pediatric Pulmonology
·
3
Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis
2024
·
Lauren N. Kormelink
, HollyAnn R. Jacobs
·
Pediatric Pulmonology
·
2
Evaluation of a pharmacist‐led smoking cessation service in a pulmonary clinic
2023
·
Sera Andras
, Erin Sherwin
, et al.
·
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
·
2
Geriatric and Student Perceptions following Student-led Educational Sessions
2018
·
Kristin Janzen
, Lauren N. Kormelink
, et al.
·
INNOVATIONS in pharmacy
·
1
PDF
Poster: 728A quality improvement initiative using pre-clinic screening to identify multidisciplinary care needs and social determinants of health in adults with cystic fibrosis
2026
·
L. Kormelink
, T. Patrick
, et al.
·
Journal of Cystic Fibrosis
Poster: 440Perspectives of medical providers and pharmacists regarding pharmacist contributions to cystic fibrosis outpatient care
2026
·
L. Kormelink
, J. Galipean
, et al.
·
Journal of Cystic Fibrosis
Documentation practices of cystic fibrosis pharmacists: An opportunity for discipline-wide quality improvement
2026
·
Hanna Phan
, Joseph V. Rosano
, et al.
·
Journal of the American Pharmacists Association
508 Linaclotide use for treatment of constipation and gastrointestinal symptoms in people with CF: a case series
2024
·
L. Kormelink
, H. Jacobs
·
Journal of Cystic Fibrosis
640 Quality improvement: increasing vitamin D levels in adults with CF
2024
·
T. Patrick
, L. Kormelink
, et al.
·
Journal of Cystic Fibrosis
Efficacy of elexacaftor/tezacaftor/ivacaftor in decreasing severe cystic fibrosis-related exacerbations: a retrospective, within-group study
2024
·
Christian Rhudy
, Lauren Kormelink
, et al.
436 Documentation practices of cystic fibrosis pharmacists: an opportunity for discipline-wide quality improvement
2023
·
H. Phan
, J. Rosano
, et al.
·
Journal of Cystic Fibrosis
PDF
376 Impact of total care pharmacy services provided by a health system specialty pharmacy on long-term medication adherence in peoplewith cystic fibrosis
2023
·
L. Kormelink
, T. Platt
, et al.
·
Journal of Cystic Fibrosis
PDF
431 Evolution of pharmacy services at U.S. CFF-accredited centers: 10 years later
2023
·
P. Grube
, E. Autry
, et al.
·
Journal of Cystic Fibrosis
PDF
252 Real-world efficacy of elexacaftor/tezacaftor/ivacaftor in decreasing cystic fibrosis pulmonary exacerbations in health-system based specialty pharmacy patients
2022
·
C. Rhudy
, L. Kormelink
, et al.
·
Journal of Cystic Fibrosis
PDF
502 Retrospective reviewof vancomycin trough versus area under the curve monitoring in pediatric and adult patients with cystic fibrosis
2022
·
B. Mitchell
, L. Kormelink
, et al.
·
Journal of Cystic Fibrosis
PDF
Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Severe Cystic Fibrosis-Related Exacerbations in Specialty Pharmacy Patients and Vulnerable Subgroups: A Retrospective, Pre-Post Study
2022
·
Christian Rhudy
, Lauren Kormelink
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
20
Citation count:
79
H-index:
4
I10-index:
3
Year
Topic
Type